

Patients Overestimate Their ICD Survival Gain

BY BRUCE JANCIN
Denver Bureau

CHICAGO — Most heart failure patients greatly overestimate the survival benefit provided by implantable cardioverter defibrillators, according to a new survey, Dr. Garrick C. Stewart reported at the annual scientific sessions of the American Heart Association.

The problem stems in part from the common practice of reporting clinical trial outcomes in terms of percent reduction in mortality. It creates confusion among patients, the public, and even physicians. This figure is actually a percent of a percent and is far greater than the number of deaths prevented or delayed, which is what really matters, added Dr. Stewart of Brigham and Women's Hospital, Boston.

"We advocate reporting event rates in persons per 100 to translate more clearly



More than half of those surveyed said they expected an ICD would save at least 50 lives per 100 recipients over 5 years.

DR. STEWART

such information for our patients. We cannot stop reminding our patients and ourselves that heart failure remains a fatal disease from which most deaths occur slowly," he stressed.

Dr. Stewart presented the results of a written survey completed by 104 patients with symptomatic heart failure who fit the profile of the study population in the landmark Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) which established the efficacy of ICDs for primary prevention of cardiac arrest. These were patients with a left ventricular ejection fraction below 35% and no history of cardiac arrest or syncope. Two-thirds already had an ICD.

More than half of those surveyed indicated they expected an ICD would save at least 50 lives per 100 recipients over a 5-year period. In reality, Dr. Stewart noted, SCD-HeFT showed the benefit is 7-8 lives saved.

"Frankly, the benefit is just not as big as we think," observed coinvestigator Dr. Lynne Warner Stevenson, codirector of the cardiomyopathy and heart failure clinic at Brigham and Women's Hospital and professor of medicine at Harvard Medical School, Boston.

"We frequently have patients referred to us from other centers where they've been told that they must have an ICD put in place or they'll die. We think that's quite a disservice because it implies that the ICD will make them immortal," she continued.

Two-thirds of survey participants who actually had an ICD thought the device would save their own lives. Fifty-five percent indicated they wouldn't deactivate it even if they were getting daily shocks, 70% would keep it on if they were dying of

cancer, and 100% would keep the device on even if they were continuously struggling to breathe.

Dr. Stewart and Dr. Stevenson advocate a highly systematic approach to consenting patients for an ICD if they've never had a life-threatening arrhythmia.

"We actually have a script we use that says if we put an ICD in 100 patients with heart disease like yours, over the next 5 years we would expect that 30 patients would die anyway, 7 or 8 would be saved

by the ICD, 10-20 would have a shock they don't need, 5-15 would have other complications, and the rest would not experience their device at all," Dr. Stevenson said.

After hearing all of this, roughly one-third of patients still want a device, one-third decide they definitely don't, and one-third want to think it over some more.

Underscoring the point that ICDs partially protect against sudden arrhythmic death but don't prevent a slower death from pump failure, Dr. Jean-Yves F. Le

Heuzey presented outcome data on 2,418 patients who got an ICD at 22 French hospitals during 2001-2003.

Mortality was 11.3% by 2005. Forty-two percent of deaths resulted from pump failure, 8.7% from cardiac arrest with electromechanical dissociation, and 6.2% were due to arrhythmic storm. Cancer and septic shock each accounted for 6.5% of deaths, said Dr. Le Heuzey, professor of cardiology at George Pompidou European Hospital, Paris. ■

plateletNEWS.org

Breakthrough platelet information and education

FACULTY LIST

Dean J. Kereiakes, MD

The Heart Center of Greater Cincinnati and The Lindner Research Center at The Christ Hospital Cincinnati, Ohio

Norman E. Lepor, MD

Cedars-Sinai Medical Center Los Angeles, California

Peter B. Berger, MD

Geisinger Health System Danville, Pennsylvania

Marc Cohen, MD

Newark Beth Israel Hospital Newark, New Jersey

James J. Ferguson, MD

Texas Heart Institute at St. Luke's Episcopal Hospital Houston, Texas

Christopher B. Granger, MD

Duke University Medical Center Duke Clinical Research Institute Durham, North Carolina

Paul A. Gurbel, MD

Johns Hopkins University School of Medicine Sinai Hospital Baltimore, Maryland

Alan D. Michelson, MD

University of Massachusetts Medical School Worcester, Massachusetts

Gilles Montalescot, MD

Institut de Cardiologie Pitié-Salpêtrière Paris, France

Gregg W. Stone, MD

Columbia University Medical Center New York, New York

Stephen D. Wiviott, MD

Brigham and Women's Hospital Boston, Massachusetts

Introducing:

plateletNEWS.org/print3—dedicated to advancing knowledge in the diagnosis, prevention, and treatment of platelet-related thrombotic complications of cardiovascular disease.

plateletNEWS.org/print3 offers timely and comprehensive information through direct access to experts, CME and non-CME activities, literature reviews, late-breaking trial updates, clinical case scenarios, and more.

CME Center

- Video Webcasts on Relevant Issues
- Interactive Patient Case Scenarios
- Downloadable Slide Presentations
- Journal Clubs
- Textbook Chapters
- Review Articles

Expert Zone

- *Ask the Expert* section—pose questions to the expert of your choice on our committee
- *Welcome to My Practice*—showcase of prominent national cardiology institutions

Additional Resources

- Literature Reviews
- Article Reprints
- E-Newsletter

Visit plateletNEWS.org/print3 to enhance your understanding of platelet inhibition and thrombotic complications. Register today to receive timely educational materials.



This program is supported by an educational grant by Daiichi Sankyo, Inc. and Eli Lilly and Company. Certified CME activities on plateletNEWS.org/print3 have been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Elsevier. The EOCME is accredited by the ACCME to provide continuing medical education for physicians.

